India, May 13 -- image credit- freepik

Vyome Holdings, Inc. has announced the signing of an agreement with Mumbai-based Impetis Biosciences, a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1/3 inhibitor and a selective JAK1 inhibitor.

Janus kinase (JAK) inhibitors are immunomodulatory drugs that treat autoimmune and inflammatory conditions by blocking JAK enzymes. Several JAK inhibitors are US FDA-approved to treat a wide range of disease conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, alopecia areata (baldness), atopic dermatitis (eczema), etc.

However, the FDA has previously issued warnings that certain of these older-generati...